Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.19 | N/A | +1.91% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.19 | N/A | +1.91% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about the company's future prospects. They focused on the strength of their product pipeline and ongoing innovations.
Management highlighted ongoing research and development efforts.
They emphasized the importance of their pipeline in driving future growth.
Gilead Sciences reported a positive surprise in EPS, indicating better-than-expected profitability. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction remains unclear, as specific movement data is not available.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ON SEMICONDUCTOR COR
Feb 1, 2021